Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study
Journal of Bone and Mineral Metabolism · 30.10.2026
DOI: 10.1007/s00774-026-01775-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone and Mineral Metabolism, online erschienen am 30.10.2026. Verfasst von Gizem Teker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA, USA. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Department of Medicine, Boston Medical Center - Brighton, 736 Cambridge St, Boston, MA, 02135, USA. sramadan@bu.edu.
- Department of Medicine, Boston Medical Center - Brighton, 736 Cambridge St, Boston, MA, 02135, USA.
- Division of Endocrinology, Boston Medical Center - Brighton, Boston, MA, USA.
Zitieren
APA
Teker, G., Ramadan, S., Bardak, A. E., Vehbi, S., Siramongkholkarn, S., & He, Z. (2026). Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study. Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-026-01775-3
Vancouver
Teker G, Ramadan S, Bardak AE, Vehbi S, Siramongkholkarn S, He Z. Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study. Journal of Bone and Mineral Metabolism. 2026. doi:10.1007/s00774-026-01775-3
BibTeX
@article{Teker2026,
author = {Teker, Gizem and Ramadan, Sara and Bardak, Ali Emre and Vehbi, Sezan and Siramongkholkarn, Smuch and He, Zhiheng},
title = {Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study},
journal = {Journal of Bone and Mineral Metabolism},
year = {2026},
doi = {10.1007/s00774-026-01775-3}
}
EUVIMED